AnalystBook Research · Company Intelligence

CareTrust REIT, Inc.

CTRENYSE

Built from CareTrust REIT, Inc.'s own SEC filings · updates as new filings land · sources cited throughout

or browse all covered companies

Revenue was $1.2M, while Net income increased 156.3% to $320.5M.

The read at a glance✓ Audited against SEC data
  • ScaleFY2025 revenue $1.2MOK
  • ProfitabilityNet income $320.5MOK
  • Cash generationFree cash flow N/ANote
  • AccountingNo applicable forensic screenNote
  • Insiders0 buys; 0 sells in 365 daysNote
  • Capitaldividends paid were $259.3MNote

Business

CareTrust REIT, Inc.: We have no reason to believe that this information is inaccurate in any material respect, but we cannot provide any assurance of its accuracy.

Where the revenue comes from

Fiscal 2025, as CareTrust REIT, Inc. reports it. History and quarterly detail are in the app.

  • Reportable$476.4M

Leadership changes

From CareTrust REIT, Inc.'s own filings, the day they're filed.

  • Gregory K. Stapley · Directors · appointmenteff. 2026-01-01
  • Derek Bunker · Chief Financial Officer · appointmenteff. 2026-01-01
  • William M. Wagner · Chief Financial Officer · departureeff. 2025-12-31

Latest filings

  • 8-K · Company announcement2026-08-06
  • 10-Q · Quarterly report2026-08-06
  • 8-K · Company announcement2026-05-21
  • 8-K · Company announcement2026-05-20
  • 8-K · Company announcement2026-05-07
In the full recordFree for 14 days
  • What changed🔒
  • Insider signal🔒
  • Growth quality🔒
  • Margins & accounting🔒
  • Capital allocation🔒
  • Real risks🔒
  • The long arc🔒
  • Company history🔒
  • The filings, readable — with what changed vs the prior year highlighted🔒
  • Full financial statements, industry-aware, sources cited throughout🔒
  • Forensic score history & components — the trend, not one year🔒
  • Ownership: insider buys/sells, clusters, activist stakes🔒
  • Ana — ask about CareTrust REIT, Inc., every answer cited to the official filings🔒

Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.

14-day free trial, no credit card. For research purposes only; not investment advice.